Four cardiometabolic-related news items have been observed: Alnylam (press release; slides) and Regeneron (press release; slides) hosted their respective Q2 ’23 earning calls; Ionis announced it entered a collaboration and license agreement with Novartis for the discovery, development, and commercialization of a medicine for patients with Lp(a)-driven CVD (view press release); and NeuroBo Pharmaceuticals announced it received IRB approval for its first site to proceed with the Ph2a clinical trial of DA-1241 (GPR119 agonist) for the treatment of NASH (view press release). Below, FENIX provides highlights and insights for the respective news items.